Palvella Therapeutics says the FDA has accepted its application for QTORIN™ rapamycin to treat microcystic lymphatic malformations and granted it Priority Review. The FDA’s target date for a decision is February 28, 2027, putting the company’s lead program on a regulatory timeline that could support a U.S. launch in the first half of 2027 if approved.
The company also outlined progress across its pipeline and reported $236.7 million in cash, cash equivalents and short-term investments at September 30, 2026.
Key details
-
FDA review of lead drug: QTORIN rapamycin is being developed for microcystic lymphatic malformations, a serious, lifelong condition affecting an estimated more than 30,000 diagnosed children and adults in the U.S. Palvella says it could be the first FDA-approved treatment for the disease.
-
Launch preparations: Palvella is preparing for a standalone U.S. commercial launch in the first half of 2027, conditional on FDA approval. It says key commercial, medical and patient-services capabilities are in place and that it is recruiting additional staff.
-
Clinical evidence cited by the company: Recent conference posters on the Phase 3 SELVA study reported improvements in disease severity and features including lesion height, vesicle appearance, and leaking or bleeding in children. Other presentations described participant-reported benefits and treatment satisfaction. Palvella also reported low, stable systemic rapamycin exposure over 24 hours, with mean exposure at least 40 times lower than reported with oral sirolimus.
-
Cutaneous venous malformations: A Phase 2 poster reported improvements in overall disease severity and reduced lesion bleeding among pediatric participants treated with QTORIN rapamycin. Palvella said it remains on track to begin a Phase 3 trial in the fourth quarter of 2026.
-
Angiokeratomas: Palvella is enrolling patients in LOTU, a multicenter Phase 2 study of QTORIN rapamycin for clinically significant angiokeratomas. The program has FDA Fast Track designation; the company expects topline results in the second half of 2027. It estimates that more than 50,000 people in the U.S. have the condition and says there are no FDA-approved therapies.
-
DSAP program: Palvella presented a poster on QTORIN pitavastatin for disseminated superficial actinic porokeratosis. The available announcement does not provide further details on the poster’s findings.
-
Additional programs: The company said it expects to announce two more programs by year-end. It also received a third year of FDA grant funding to support the SELVA trial and its open-label extension study.
-
Financial position: Palvella reported $236.7 million in cash, cash equivalents and short-term investments as of September 30, 2026. The available announcement does not provide revenue, loss or cash-use figures.
Plain-English implications
The FDA’s acceptance of the application and Priority Review set a defined decision date for Palvella’s lead candidate, while the company is spending ahead on launch readiness. Any launch remains contingent on approval. The reported cash balance is a key measure of the resources available as Palvella pursues that review and advances its other clinical programs.